Soluble guanylyl cyclase (sGC) is a key protein in the nitric oxide (NO)/-cGMP signaling pathway. sGC activity is involved in a number of important physiological processes including smooth muscle relaxation, neurotransmission and platelet aggregation and adhesion. Regulation of sGC expression and activity emerges as a crucial factor in control of sGC function in normal and pathological conditions. Recently accumulated evidence strongly indicates that the regulation of sGC expression is a complex process modulated on several levels including transcription, post-transcriptional regulation, translation and protein stability. Presently our understanding of mechanisms governing regulation of sGC expression remains very limited and awaits systematic investigation. Among other ways, the expression of sGC subunits is modulated at the levels of mRNA abundance and transcript diversity. In this review we summarize available information on different mechanisms (including transcriptional activation, mRNA stability and alternative splicing) involved in the modulation of mRNA levels of sGC subunits in response to various environmental clues. We also summarize and cross-reference the information on human sGC splice forms available in the literature and in genomic databases. This review highlights the fact that the study of the biological role and regulation of sGC splicing will bring new insights to our understanding of NO/cGMP biology.
It has been more than 30 years since nitric oxide (NO), a gaseous free radical, was recognized as a critical physiologic signaling molecule. Since that time the list of known NO-directed functions has grown substantially and includes the regulation of smooth muscle function in vascular and gastrointestinal systems, inhibition of platelet aggregation and adhesion, neurotransmission and neuromodulation, regulation of cellular respiration and cytotoxicity, mitochondrial biogenesis and immune defense [1] . In living organisms NO is synthesized enzymatically from L-arginine by the family of nitric oxide synthases (NOS), including endothelial (eNOS), neuronal (nNOS) and inducible (iNOS) isoforms. Generated NO is connected to downstream signaling by the enzyme soluble guanylyl cyclase (sGC), which produces the secondary messenger cyclic guanosine monophosphate (cGMP) from guanosine triphosphate (GTP). NO binding to sGC heme moiety increases the production of cGMP more than a hundred fold [2] . Increases in cGMP concentrations regulate activity of a number of cGMP-dependent proteins, including cGMP-binding protein kinases, cGMP-dependent phosphodiesterases and cyclic nucleotide gated ion channels [3] .
The use of organic nitrates in the treatment of angina pectoris and heart failure dates back to the 19th century [4] . However, it was only when the mechanism of action of these nitro-vasodilators was demonstrated to depend on sGC function, that the enzyme attracted the deserved attention from the scientific community [5] . Studies examining the regulatory mechanisms directly modulating sGC activity and/or expression, which could be used to circumvent the direct use of NO-donors, have been motivated further by the discovery of NO cytotoxicity and by the negative side-effects of prolonged use of nitro-vasodilators [6] .
sGC properties and its expression pattern sGC is a heme-containing obligatory heterodimer composed of a and b subunits [7] . Its expression has been detected in all studied tissues, albeit at varying levels and with different subunit compositions [8] . Although sGC was originally purified from a cytosolic fraction, it was subsequently found associated with cellular membranes in a variety of cell types [9] [10] [11] [12] [13] [14] [15] . Each sGC subunit has two isoforms (a1/a2 and b1/b2) encoded by a total of 4 separate genes. Only sGC heterodimers containing the b1 subunit have been shown to possess catalytic activity in vivo [16] . While a subunits (a1 and a2) have similar catalytic properties, they differ in their tissue and subcellular distribution [8, 13, 16] . The functional role of the b2 subunit still remains unclear since native functional heterodimers containing this b2 subunit have yet to be isolated from tissues [17] . Recombinant b2 homodimer is reported to have relatively low enzymatic activity [18] , while overexpression of b2 was shown to reduce NO-sensitive sGC activity by outcompeting b1 for heterodimerization with the a1 subunit [19] .
sGC function in mammalian physiology
With the generation and characterization of sGC knock-out (GC-KO) mouse strains has come a greater understanding of these genes' roles in mammalian physiology (for an excellent review see [20] ). Mouse knock-out studies have demonstrated that NOdependent vascular relaxation and platelet aggregation depend exclusively on the functional expression of a1/b1 and a2/b1 sGC heterodimers [21, 22] . Moreover, targeted disruption in vascular smooth muscle cells (VSMC) is sufficient to induce hypertension in mice, underscoring the importance of sGC in the maintenance of normal blood pressure [23] . Surprisingly, GC-KO mice also present with severe developmental and gastrointestinal (GI) disorders, revealing important roles for sGC in embryonic development and GI function [22] . The significance of individual sGC subunits in overall enzyme activity was demonstrated by analysis of knockout strains for b1, a1 and a2 sGC subunits. The expression of b1 subunit was found to be non-redundant for sGC enzymatic function [21] . The a1 and a2 sGC subunits demonstrated partially overlapping roles in vascular and gastric nitrergic smooth muscle relaxation [8, 24, 25] . However, several important physiological functions, such as development of testosterone-dependent hypertension, NO-mediated pulmonary vasodilation and vascular remodeling in chronic hypoxia appeared to be mediated specifically by a1 and not by the a2 sGC subunit, pointing to divergent roles of a sGC genes [26] [27] [28] [29] . Recent data demonstrating disrupted long term potentiation (LTP) in visual cortex and hippocampal slices isolated from a2 knock-out mice suggests a non-redundant role for this subunit in LTP expression [30, 31] .
Regulation of sGC expression

Why is it important?
Despite its critical role in NO signaling, there is rather limited information regarding how the regulation of expression of individual sGC subunits affects NO-dependent processes. The importance of sGC expression for regulation of activity is underscored by numerous studies which demonstrate that changes in mRNA and protein levels are associated with the impairment of vascular function in cardiovascular disorders. Decreased sGC expression is proposed to be one of the mechanisms underlying the development of endothelial dysfunction and tolerance to organic nitrates [32] [33] [34] [35] . Impaired sGC expression is also implicated in the development of hypertension [36, 37] and atherosclerosis [38] . Down-regulation of sGC occurs both with aging and in response to a high salt diet in aortas of spontaneously hypertensive (SHR) rats [34, 39] . Finally, age-dependent decreases in estrogen level and associated increased vascular stiffness of aortas were shown to correlate with decreased levels of a1 and b1 sGC [40] .
Detailed studies of sGC-KO mice additionally highlight the importance of regulating individual sGC subunit expression. Tamoxifen-induced tissue-specific knockout of the b1 subunit in vascular smooth muscle demonstrated that NO-stimulated cGMP production was reduced in a dose-dependent manner that correlated with gradual decreases in b1 sGC protein levels [23] . Deletion of a1 sGC, has been shown to significantly reduce basal and NOstimulated sGC activity in mouse aortas [26, 41] , left ventricular myocardium [26] and gastric tissues [25, 27, 28, 42] . This decreased sGC function was sufficient to compromise myocardial function [26] and promote hormone-dependent hypertension in hypoxic stress conditions [29] . Yet the severity of these phenotypes was partially compensated by changes in the expression of the a2 sGC subunit. Thus, all accumulated evidence directly indicates that regulation of the expression of a1, a2 and b1 genes is vital to maintain the integrity of NO/cGMP signaling in mammalian physiology.
Regulation of sGC expression by changes in mRNA steady-state levels
It has been demonstrated that the expression of sGC subunits may be modulated at the levels of mRNA abundance and/or protein stability (for excellent reviews on this subject see [43, 44] ). Our review focuses primarily on regulation occurring at the mRNA level, emphasizing the specific role of the alternative splicing of sGC subunit genes. Multiple reports demonstrate that the regulation of steady-state sGC mRNA levels occurs in response to environmental clues. Clear differences in steady-state mRNA levels of individual sGC subunits have been observed in response to a number of extracellular and intracellular stimuli (see Fig. 1 ). The a1 and b1 sGC mRNAs are affected by inflammatory regulators such as lipopolysaccharide (LPS), interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a), NO, reactive oxygen species (ROS), and by increased cAMP and cGMP levels [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] . sGC mRNA expression is regulated by the nerve growth factor (NGF) [57] . Changes in the levels of various sex hormones also alter mRNA steady-state levels. Estrogen is known to rapidly down-regulate the a1 and b1 sGC in rat uterus [59] , while in anterior pituitary gland it exerts a dual effect by decreasing b1 and increasing a1 sGC mRNA levels [58] . The a1 sGC mRNA is also increased upon exposure to androgen, which is thought to contribute to the proliferation of prostate cancer cells [60] . Thus, it is clear that sGC mRNA levels are regulated by multiple alternative mechanisms in a tissue-specific (cell-type specific) and a stimuli-specific manner. What remains unclear is the precise role of alternative RNA splicing in this process, given that the majority of studies have been done without quantification of individual RNA transcript levels. Instead, primers and probes typically have been targeted to the most conserved parts of sGC genes sequences, which are present in the majority of splice variants generated from the particular gene.
The maintenance of steady-state mRNA levels for mammalian genes is achieved not only through transcription, but also by regulation of pre-mRNA splicing and mRNA stability (see Fig. 1 ). Furthermore, the amount of mRNA available for translation is also dependent on polyadenylation, nuclear to cytoplasmic transport, subcellular localization/sequestration, and miRNA targeting. Below we will summarize the existing data related to the regulation of steady-state levels of sGC mRNA while highlighting the role of alternative splicing in this process.
Transcription initiation
For many years the rate of transcription initiation was considered to be a principal mode of regulation of mRNA abundance. We now know that post-transcriptional mechanisms like mRNA stability, splicing, intracellular localization/sequestration, and miRNAs play critical roles in gene regulation [61] [62] [63] . However, the regulation of transcription initiation remains an important and, from a metabolic point of view, the most economical way to modulate the expression of a particular gene.
The first study regarding a1 and b1 sGC transcriptional regulation was an examination of promoters from the Medaka fish. The a1 and b1 genes from Medaka fish are localized on the same chromosome and separated by less than 1000 base pairs. Their transcription appears to be cis-regulated in a polycistronic manner [64] . Similar regulation was proposed for human a1 and b1 sGC genes [64] , as they are also localized to a single small chromosomal region [65] . However, the results from several laboratories demonstrated that all four mammalian sGC genes (a1, a2, b1 and b2) are transcribed independently. In humans, the a2 and b2 sGC, are localized to different chromosomes, 11 and 13 respectively, most definitely precluding a cis mode of transcriptional regulation. Promoter regions of a1 and b1 sGC in human and rodents (mice and rats) have been mapped ectopically to define specific sequences required for transcriptional activity [66] [67] [68] [69] [70] . The promoters for a2 and b2 sGC genes remain to be examined.
Several conserved features exist between a1 and b1 sGC promoters in humans and rodents. The core promoter regions of a1 and b1 sGC are TATA-less and contain a number of similar transcription factor (TF) binding sites. Importantly, each has a CCAAT-binding site, which is associated with the CBF (NF-Y) transcriptional factor, and shown to be essential for house-keeping promoter activity in all species investigated to date [66, 67, 69, 70] . The presence of these common elements suggests a potential for coordinated regulation of a1 and b1 sGC transcription.
Consistent with the reports indicating that sGC expression is regulated during embryonic development [71] [72] [73] [74] [75] , TF binding sites involved in morphogenesis and differentiation, such as c-Myb, AP1, GATA1, Nkx-2.5 and Lyf-1, have been identified in the a1 and b1 sGC promoters [66, 67, 69] . Additionally, human and rodent a1 promoters possess a variety of binding sites for stress response TFs, including NFAT, NF-kB, AP1 and SP1. Reporter construct studies TNFa or NO donors) mapped to NF-kB and CBF binding sites [67] . Finally, NFATc3 (nuclear factor of activated T cells isoform c3)
has been shown to promote the transcription of the a1 sGC gene in response to pulmonary hypoxia in mice [76] . Thus, accumulated evidence indicates that transcription plays an important role in regulation of sGC mRNA levels, especially in response to inflammation and during embryonic development. Still, our understanding of the mechanisms governing transcription of all four sGC genes remains very limited and awaits further investigation.
mRNA stability
The bioavailability of newly transcribed RNA for translation depends on several important factors including accurate processing, export to the cytoplasm, and mRNA stability. It is the balance of these events that determines overall steady-state mRNA levels. For sGC transcripts, mRNA stability is known to play an important role and is probably the best studied among these regulatory mechanisms. The rate of mRNA degradation is determined by intrinsic properties of each individual RNA primary sequence, and a number of mechanisms regulate this process. Multiple studies indicate that stability of sGC mRNAs is tightly regulated in mammalian cells and varies in response to different stimuli. For example, elevated levels of NO, cyclic nucleotides and growth factors have been shown to modulate the stability of a1 and b1 sGC mRNAs [50, 51, 57, 77] . Exposure to N-methyl-D-aspartate (NMDA) was found to increase the stability of a2 sGC mRNA in rat cerebellar granule cells [78] .
The feedback mechanism that destabilizes sGC transcripts in response to elevated cAMP/cGMP levels following cell stimulation with NO-donors or forskolin was recently unraveled [51, 77] . HuR (Human-Antigen R) protein acts to stabilize a1 and b1 sGC transcripts by binding Adenine-and Uracil-rich elements (ARE) located in the 3 0 -untranslated regions (UTRs). It has been demonstrated that HuR down-regulation in response to elevated cAMP/cGMP levels increases the rate of a1 and b1 mRNAs degradation in rat aortic cells [51] . In the spontaneously hypertensive rat (SHR) model, reductions in HuR protein are associated with decreased a1 and b1 sGC mRNA and contribute to the development of age-dependent hypertension [52] . It was also shown that the exposure to chronic hypoxia decreases cytosolic levels of HuR protein with concomitant reduction of a1 sGC mRNA in murine pulmonary vascular smooth-muscle cells [76] .
In neuronal cells, a2 sGC mRNA degradation is found to be regulated by Adenosine-Uridine binding factor 1 (AUF1). AUF1, along with HuR protein, is shown to bind ARE sites located in the 3 0 UTR of the a2 sGC [79] . Interestingly, N-methyl-D-aspartic acid (NMDA) treatment of rat cerebellar granule cells elevates a2 sGC mRNA levels, which is associated with a decrease in AUF1, but not HuR protein. These data suggest that multiple RNA-binding proteins are involved in the regulation of sGC mRNA stability, and that they might act in both tissue-specific and stimuli-specific manners. It seems likely, that a plethora of factors involved in the regulation of sGC mRNA stability remains to be discovered. Among those, regulation by small inhibitory RNAs and microRNAs is an intriguing and yet unexplored possibility.
sGC splicing: literature and database analysis Alternative splicing allows for generation of different transcripts from the same precursor RNA by incorporation or exclusion of various exon sequences. Changes in the UTR regions of RNA introduced by splicing have been shown to affect the stability, export, localization, and translational capacity of the transcript, either through modifications of RNA structure or by introducing/ eliminating binding sites for various RNA-binding regulatory proteins. Variations involving coding sequence lead to alteration in the properties of encoded proteins, thus increasing the functional diversity of the genome. Introduction of pre-mature stop codons by splicing regulates RNA stability through the activation of nonsense-mediated decay (NMD) pathways. Recent transcriptome analysis indicates that more than 90% of human genes are alternatively spliced, making it one of the most important post-transcriptional regulatory mechanisms [63] .
Several studies have demonstrated that transcripts derived from all sGC genes undergo alternative splicing [73, [80] [81] [82] [83] [84] . Furthermore, there is a remarkable diversity of sGC mRNA transcripts deposited in the GenBank databases. However, the mechanisms involved in the regulation of sGC splicing and biological roles of different splice forms remains, for the most part, unknown. There is also a lack of a systematic unifying nomenclature for sGC transcripts. The recent sorting and validation of a1 sGC gene transcripts by NCBI (National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov) was a welcome first step in the classification of a1 sGC splice forms [85] . However, new transcript and protein isoform names have been assigned by NCBI without taking into account already published reports. To fill this gap, we summarize and cross-reference the information available in the literature and genomic databases for all genes of human sGC subunits. In our analysis we have relied extensively on the UCSC Browser tool, which provides cross annotations from both NCBI and Ensembl databases [86] .
a1 sGC (GUCY1A3 -Chromosome 4q32.1). The a1 gene is found to be expressed in all examined tissues, with the highest levels detected in vasculature [8] . To date, a1 splice variants are the most diverse and best characterized group in comparison with other sGC genes. Recently, the variety of human a1 transcripts existing in the NCBI database was revised and consolidated into seven types, which encode four different protein isoforms named A, B, C and D. We have assembled and cross-referenced them, highlighting changes in exon composition and encoded polypeptides (Fig. 2) . All a1 transcripts can be sub-divided into two groups based on the encoded proteins. The first group includes transcripts 1-4, which encode an identical 690 aa protein, named isoform A (canonical a1 sGC). These transcripts differ from each other only in their 5 0 -and 3 0 -UTR sequences which, as discussed previously, are likely to play a role in regulation of mRNA processing. In the second group, transcripts 5-7 each encodes a unique polypeptide named isoforms B, C and D. Several of these splice forms have been assigned conventional names at the time of their original biochemical characterization (Fig. 2) .
Within the second group, alternative splice variants lacking the canonical translational start site were first reported by Ritter et al. [87] . Through an analysis of transcripts present in the NCBI database, we identified additional splice forms encoding polypeptides with deletions in C-and N-termini of the a1 protein [84] . Using RT-and qRT-PCR analyses we demonstrated that transcripts encoding truncated a1 isoforms are differentially expressed in normal human tissues. Characterization of these proteins performed in two different cell models, BE2 human neuroblastoma cells and Sf9 insect cells, demonstrated that encoded deletions generate sGC heterodimers with altered functional properties. The N1-a1 variant (Transcript 6, isoform C) encodes a1 sGC protein with extensive deletion in the catalytic domain. It displays properties of a dominant negative mutant by inhibiting activity of the a1/b1 sGC heterodimer. In contrast, the C-a1 sGC splice form (Transcript 5, isoform B), encodes a fully functional protein despite an N-terminal 236 aa deletion. sGC heterodimers containing C-a1 sGC are much less sensitive to ODQ-induced oxidative protein degradation and partially protected b1 sGC levels when co-expressed together in BE2 cells [84] . In a recent report, we established that C-a1 sGC splice form is expressed at high levels during differentiation of human embryonic stem cell (hES) and its intracellular distribution varies from canonical a1 sGC subunit [73] .
The last isoform in this group (Transcript 7, isoform D) is a recently validated referenced sequence (RefSeq, NCBI) derived from human placenta and intestine libraries (http://www.ncbi.nlm.nih.-gov/nuccore/NM_001130687). This transcript is generated through the use of an alternative polyadenylation site in exon 10. The mRNA isoform is predicted to encode a polypeptide with a 66 aa deletion at the C-terminus. The deletion is located in close proximity to the catalytic domain and thus is likely to affect the catalytic properties of encoded a1 polypeptide.
Finally, at least 6 additional alternative a1 sGC transcripts not found in the NCBI Referenced Sequences (RefSeq) database, including N2-a1 described earlier by our group ( [84] , Fig. 3 , VEGA Transcript N OTTHUMT000000365787), exist in the newly updated ENCODE Genecode database [88] . These splice variants encode a variety of short N-terminal polypeptides of the a1 protein. Four out of six transcripts (VEGA Transcript N OTTHUMT000000365780, 83, 84, and 87) represent potential substrates for nonsense mediated decay (NMD) due to the presence of premature stop codons within internal exons. NMD is a mechanism that detects and eliminates aberrant mRNAs whose expression would result in truncated proteins [89] . Splicing that favors creation of transcripts targeted to NMD when the transcription rate remains unchanged would result in quick depletion of total mRNA pool (activate an ''RNA sink''). This process may function as an alternative mechanism to quickly down-regulate steady-state a1 mRNA levels. Whether this mechanism truly modulates a1 sGC levels remains to be determined. Regarding the remaining transcripts, one encodes the canonical protein isoform A (OTTHUMT00000365780) and the other is a small RNA with no appreciable ORFs (Fig. 3) . It should be noted that the reported exon 11 polyadenylation sites vary greatly among these transcripts suggesting that regulation at the 3 0 UTR may be more complex than currently recognized.
Interestingly, only a single a1 sGC transcript with altered ORF exists in the mouse NCBI RefSeq database. It encodes a splice form identical to human isoform C (Accession AK031305). The rest of the mouse transcripts encode the canonical a1 protein (isoform A) and differ only in the 5 0 -or 3 0 -UTR sequences. Evolutional conservation of isoform C between human and rodents suggests that it might play an important biological function.
a2 sGC (GUCY1A2 -Chromosome 11q22.3). The a2 transcript has a more restricted pattern of expression than the a1 sGC and it is highly abundant in neuronal tissues [8] . The canonical a2 sGC transcript contains 8 exons (NM_000855 derived from Accession X63282, BC130488, BC130484, GenBank). The first evidence that the human a2 pre-mRNA undergoes alternative splicing was reported when the a2i splice variant was described [80] . This tran- script is generated by the insertion of an alternative cassette exon after the coding exon 6 (Accession N Z50053, NCBI). Co-expression of recombinant a2i with the a2 and b1 subunits demonstrated that this splice form possess properties of a dominant negative mutant [80] , very similar to the N1-a1 variant of the a1 sGC [84] . Analysis of database sequence also reveals the existence of a third type of splice transcripts (Accession BC144033, GenBank), which is generated by an in-frame insertion of alternative exon after the coding exon 4. This exon encodes a unique 22 amino acid residues insertion in the proximity to the catalytic domain. Functional properties of this new a2 splice variant await further investigation.
Recently, the existence of a splice variant homologous to the human a2i has been revealed in the rat pituitary and liver tissues [82] . In this report semi-quantitative RT-PCR demonstrated that a2i, but not a2 sGC transcript, is up-regulated in response to estrogen in rat adult pituitary gland. This interesting observation suggests that the splicing of the a2 sGC subunit might be regulated by sex hormones in rodents. However, in the mouse non-referenced RNA database a2i is not present. Instead, three different transcripts encoding putative a2 proteins with deletions in Nand C-termini generated through exon exclusion are present (Accessions AK165150, AK147527 and AK034879, GenBank). These transcripts, which currently do not have human homologs in humans, remain an interesting subject for further investigation.
b1 sGC (GUCY1B3 -Chromosome 4q31.1). The ubiquitously expressed b1 sGC is indispensable to support sGC activity [8, 22, 23] . Changes in b1 sGC mRNA steady-state expression have been demonstrated in multiple reports; however, the precise regulatory mechanisms are not well studied. Similar to a1 sGC, there is much evidence supporting a potential regulatory role for alternative splicing despite the fact that only a single b1 RefSeq currently exists in NCBI database (NM_000857). Heterogeneity of b1 sGC transcripts was first demonstrated by Chhajlani et al. who showed the presence of two mRNA species in human lung tissue [83] . In addition to the canonical transcript, they observed a shorter mRNA (Accession AF020340, GenBank) predicted to encode a non-functional isoform containing 33 aa deletion in the proximity of catalytic domain (see Figs. 4 and 5) . No biochemical characterization of this splice form has been performed so far. Several additional non-referenced human b1 sGC transcripts are present public databases. These splice forms, their genomic organization, and changes in protein sequences are summarized in Fig. 4 . To simplify the recognition of the different b1 splice forms, they are labeled based on corresponding changes in encoded polypeptides.
As shown in Fig. 4 , there are b1 splice isoforms generated by the use of an alternate promoter 1b (that removes the canonical start codon), skipping of exon 2, inclusions of alternative exons (2 0 , 3 0 or 5 0 ) or changes involving 3 0 splice site selection for exon 10. These sequence rearrangements introduce changes in the ORF of b1 sGC and encode several polypeptides with unique deletions and insertions in N-and C-termini (Fig. 5) .
Alternative 3 0 splice site selection for exon 10 either introduces an in-frame 33 amino acid residue deletion, (b1-D33 variant) (OTT-HUMT00000365773) [83] or a 43 aa insertion (b1-D68X43 variant, OTTHUMT00000365768) (Fig. 4) . The location of these changes in the primary protein sequence suggests that these splice forms might have different catalytic properties. The b1-D68X43 variant (Accession AK307838, GenBank) also contains an extensive 68 aa deletion in the N-terminal regulatory region, resulting from insertion of a noncoding exon 2 0 , which leads to a shift in the translation initiation to exon 3. Loss of this N-terminal region is likely to lead terminus regulatory site surroundings N-,
VEGA
terminus catalytic site surroundings C-, to altered sGC regulatory properties. We observed expression of this splice form by RT-PCR analysis in a number of normal human tissues and several cancer cell lines (Sharina IG and Shah N, unpublished observation) suggesting that this variant is widely expressed in humans. Two b1 splice isoforms are generated through the inclusion of alternative exons downstream of exons 2 and 4 (b1-D26X6 and b1-X22, Fig. 4). A third isoform (b1-D68, Fig. 4) , is derived from the use of an alternative downstream promoter. As a result, the ORF now begins in exon 4 (Fig. 4 , protein sequence alignment in Fig. 5 ). The majority of b1 sGC transcripts were identified by the NEDO human cDNA sequencing project group from Tokyo, Japan (http://www.nbrc.nite.go.jp/hflcdna/cgi-bin). Changes in protein sequence of the b1 encoded by these splice variants are likely to affect catalytic and regulatory properties of the sGC heterodimers incorporating them (specific coding changes are summarized in Fig. 5) .
It is important to note that when examined in detail, the human b1 sGC splice forms have been isolated from a variety of different tissues including: lung, fetal brain, placenta, tongue tumor tissue, etc. This tissue diversity suggests a complex tissue specific splicing of the b1 sGC gene. Needless to say, the functional roles of b1 sGC splice forms, their expression profiles and biochemical properties await systematic investigation.
b2 sGC (GUCY1B2 -Chromosome 13q14.3). More than 20 years after the cloning of the b2 sGC subunit gene its biological role remains a mystery [80, 90] . According to several publications the a1/b2 heterodimer possesses very low, if any, enzymatic activity and was suggested to act as a dominant negative isoform to other subunits [19, 91] . b2 is the only known sGC subunit which is reported to possess activity as a homodimer [18] , resembling the particulate guanylyl cyclases. UniGene NCBI EST profile demonstrate that the b2 sGC transcript is expressed in several tissues, including kidney, intestine, lung, stomach, connective tissue, skin and mouth with highest level found in esophagus. The expression of b2 is detected in several tumors including esophageal and gastrointestinal (http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer).
Similar to other sGC subunits, b2 pre-mRNA undergoes alternative splicing. Several b2 splice variants have been described in the literature [17, 18, 81, 92] . The human canonical RefSeq gene is comprised of 17 exons (NR_003923) and surprisingly is listed as a non-coding RNA. The longest b2 ORF (617 aa) derives from exons 4 through 15. The presence of a stop codon in exon 14 would predict that this transcript is a potential substrate for NMD. Two alternative transcripts encode the N-terminally truncated splice isoforms corresponding to the splice variants originally described by Behrends' group (Acc. Ns CR615161 and AK296746). The b 2SV sGC generated by the skipping of exons encoding the N-terminal heme-binding domain of the protein, was isolated from human corpus cavernosum [17] . Based on the size and location of the deletion, it was suggested that sGC enzyme containing this b 2SV splice form should be NO-insensitive. Another splice form encoding an N-terminally truncated b2 sGC protein was isolated from human gastric carcinoma [81] . Both transcripts are predicted to encode C-terminal truncations resulting from alternative polyadenylation in exon 12.
Finally, in a recent report, a new splice variant with additional amino acids insertion in the N-terminus was described [92] . Interestingly, the same report demonstrated that 5 0 UTRs of two alternative b2 sGC transcripts ('canonical' and new splice form) possess active internal ribosome entry sites (IRES). Moreover, the efficiency of translation from the transcript containing the alternative 5'UTR was higher than from the 'canonical' one, supporting the concept that alternative splicing may play a role in modulating the translation of b2 sGC
Conclusions
Why is it important to study sGC splicing?
For some time we have known that sGC functions primarily as a heterodimer, comprised of two types of independent a and b subunits. A search for gene homologues uncovered the existence of four gene family members, allowing for the generation of four different heterodimers (a1/b1, a1/b2, a2/b1 and a2/b2), and perhaps a single homodimer (b2/b2), where once only a single enzyme form was described. It was the examination of these canonical sGC isoforms that first revealed differential expression and the unique functional consequences resulting from the choice of subunit composition. With the discovery of alternatively spliced sGC transcripts, we now know that enzyme complexity extends well beyond 5 types of sGC dimers. If one considers all theoretical peptide products generated by splicing: four a1, three a2, six b1, and three b2 subunits; there is the potential to generate a remarkable number of unique heterodimers.
Splicing of sGC fundamentally contributes to expression not only by giving rise to splice variants encoding sGC proteins with different biochemical properties, but also by producing transcripts with different regulatory sequences, which may affect mRNA stability, transport and translation. Alternative mRNA isoforms that differ in their 3 0 and 5 0 UTR regions, are likely to play critical roles in regulation of mRNA steady-state levels through stabilization mechanisms and/or inhibitory RNA targeting. The diversity of expressed sGC transcripts allows for dynamic spatio-temporal regulation in response to multiple physiological signals tailoring enzyme properties to better suit the molecular environment of the cell. Consideration of this observation alone is sufficient to provide compelling evidence for a crucial role of alternative splicing in regulation of sGC function.
The importance of splicing in the physiology of the NO/cGMP pathway is emphasized by the fact that other enzymes of this pathway also undergo alternative splicing. Accumulated evidence demonstrates that not only sGC, but also all NOS genes [93] [94] [95] [96] , cGMP-dependent protein kinase I [97] and several cGMP-dependant cyclic nucleotide phosphodiesterase (PDE) genes [98] [99] [100] [101] express a variety of alternatively spliced transcripts. Moreover, aberrant splicing regulation of the eNOS gene has been associated with increased risk of coronary artery disease [95] , while alternative splicing of PKGI has been implicated in the development of nitrate tolerance in vascular smooth muscle [97] . These data suggest that coordinated regulation of splicing of the enzymes participating in the NO/cGMP signaling may be involved in the development of cardiovascular disorders. Therefore, advancement in the understanding of the mechanisms of splicing will facilitate the development of new therapeutic strategies to combat vascular disorders and/or tailor the existing ones based on individual differences in the expression of splice isoforms of NO/cGMP pathway enzymes.
Studies of the regulation of sGC expression still remain in initial stages of development. All four sGC genes undergo splicing and demonstrate remarkable diversity of the transcripts. Though the biological role(s) of sGC splice forms are poorly understood, unraveling them will likely be fundamental to our understanding of sGC biology. Currently the components of splicing machinery participating in the regulation of sGC splicing remain completely unknown. A major challenge will be to define the mechanisms and splicing regulators participating in control of the exon selection on constitutive, cell-specific or stimulus-specific levels.
